Name: H-D-trans-Hyp-OMe HCl
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Synonyms

(2S,4R)-methyl 4-hydroxypyrrolidine-2-carboxylate hydrochloride

IUPAC Name

methyl (2R,4S)-4-hydroxypyrrolidine-2-carboxylate;hydrochloride

Canonical SMILES

COC(=O)C1CC(CN1)O.Cl

InChI

InChI=1S/C6H11NO3.ClH/c1-10-6(9)5-2-4(8)3-7-5;/h4-5,7-8H,2-3H2,1H3;1H/t4-,5+;/m0./s1

InChIKey

KLGSHNXEUZOKHH-UYXJWNHNSA-N

H-D-trans-Hyp-OMe HCl (Hydroxyproline methyl ester hydrochloride) is a modified form of the amino acid hydroxyproline, with a methoxy group attached to the hydroxyl group of the proline side chain. This modification provides increased stability and solubility, making it a valuable building block in peptide synthesis and protein engineering. Hydroxyproline is a key component of collagen and plays a crucial role in the structural integrity of connective tissues. As such, H-D-trans-Hyp-OMe HCl is used in the synthesis of peptides and peptidomimetics designed to mimic collagen or support collagen formation, which is essential in both wound healing and tissue regeneration.

In the field of drug development, H-D-trans-Hyp-OMe HCl is used as a component in the design of peptide-based therapeutics targeting diseases related to connective tissue disorders. The compound is incorporated into peptides that mimic collagen's structure or that are involved in the modulation of collagen metabolism. These peptides are being explored for the treatment of conditions such as osteoarthritis, fibrotic diseases, and wound healing disorders. By enhancing collagen synthesis or preventing excessive collagen breakdown, therapies based on H-D-trans-Hyp-OMe HCl may offer novel approaches to treating these challenging conditions.

H-D-trans-Hyp-OMe HCl is also utilized in the synthesis of biomaterials for tissue engineering. Hydroxyproline, as a key amino acid in collagen, is integral to creating scaffolds that promote cell adhesion, tissue regeneration, and the repair of damaged tissues. By incorporating H-D-trans-Hyp-OMe HCl into collagen-like peptides or copolymers, researchers can design materials that mimic the extracellular matrix, offering a more biocompatible environment for tissue growth. This application is particularly valuable in regenerative medicine, where the goal is to restore or replace damaged tissues such as skin, cartilage, or bone.

Another critical application of H-D-trans-Hyp-OMe HCl is in the study of collagen synthesis and folding. The compound is used in research focused on understanding the role of hydroxyproline in collagen stability and the formation of its triple helix structure. It has been shown that modifications to hydroxyproline residues can affect collagen folding, stability, and cross-linking. By incorporating H-D-trans-Hyp-OMe HCl into model peptides, researchers can better understand the biochemical processes that govern collagen's structural integrity, with implications for understanding various collagen-related diseases such as scurvy, osteogenesis imperfecta, and fibrosis.

1. Dissociative recombination of HCl+, H2Cl+, DCl+, and D2Cl+ in a flowing afterglow

Justin P Wiens, Thomas M Miller, Nicholas S Shuman, Albert A Viggiano J Chem Phys. 2016 Dec 28;145(24):244312. doi: 10.1063/1.4972063.

Dissociative recombination of electrons with HCl+, H2Cl+, DCl+, and D2Cl+ has been measured under thermal conditions at 300, 400, and 500 K using a flowing afterglow-Langmuir probe apparatus. Measurements for HCl+ and DCl+ employed the variable electron and neutral density attachment mass spectrometry (VENDAMS) method, while those for H2Cl+ and D2Cl+ employed both VENDAMS and the more traditional technique of monitoring electron density as a function of reaction time. At 300 K, HCl+ and H2Cl+ recombine with kDR = 7.7±2.14.5 × 10-8 cm3 s-1 and 2.6 ± 0.8 × 10-7 cm3 s-1, respectively, whereas D2Cl+ is roughly half as fast as H2Cl+ with kDR = 1.1 ± 0.3 × 10-7 cm3 s-1 (2σ confidence intervals). DCl+ recombines with a rate coefficient below the approximate detection limit of the method (≲5 × 10-8 cm3 s-1) at all temperatures. Relatively slow dissociative recombination rates have been speculated to be responsible for the large HCl+ and H2Cl+ abundances in interstellar clouds compared to current astrochemical models, but our results imply that the discrepancy must originate elsewhere.

2. Standardized Hybrid Closed-Loop System Reporting

Viral N Shah, Satish K Garg Diabetes Technol Ther. 2021 May;23(5):323-331. doi: 10.1089/dia.2020.0622. Epub 2020 Nov 25.

The hybrid closed-loop (HCL) system has been shown to improve glycemic control and reduce hypoglycemia. Optimization of HCL settings requires interpretation of the glucose, insulin, and factors affecting glucose such as food intake and exercise. To the best of our knowledge, there is no published guidance on the standardized reporting of HCL systems. Standardization of HCL reporting would make interpretation of data easy across different systems. We reviewed the literature on patient and provider perspectives on downloading and reporting glucose metric preferences. We also incorporated international consensus on standardized reporting for glucose metrics. We describe a single-page HCL data reporting, referred to here as "artificial pancreas (AP) Dashboard." We propose seven components in the AP Dashboard that can provide detailed information and visualization of glucose, insulin, and HCL-specific metrics. The seven components include (A) glucose metrics, (B) hypoglycemia, (C) insulin, (D) user experience, (E) hyperglycemia, (F) glucose modal-day profile, and (G) insight. A single-page report similar to an electrocardiogram can help providers and patients interpret HCL data easily and take the necessary steps to improve glycemic outcomes. We also describe the optimal sampling duration for HCL data download and color coding for visualization ease. We believe that this is a first step in creating a standardized HCL reporting, which may result in better uptake of the systems. For increased adoption, standardized reporting will require input from providers, patients, diabetes device manufacturers, and regulators.